Tb) have been produced mainly via a proton-induced spallation reaction on a tantalum target combined with on-line mass separation at the CERN-ISOLDE facility [6] [7] [8] . A high percentage of the 1.4 GeV protons delivered by the proton synchrotron booster do not interact with the ISOLDE targets and therefore, the CERN-MEDICIS facility was established to produce isotopes for medical applications by inducing spallation reactions in a secondary target. At CERN-MEDICIS, off-line mass separation is applied to isolate isotopes of the same A/q value 6, 7 . Terbium-155 sources used in this study were collected after mass-separation by implantation of the ion beam (155 A/q) into zinc-coated gold foils. Further chemical separation is still required as mass separation is unable to differentiate between isobaric and pseudo-isobaric species. Removal of the foil matrix is also required.
Four terbium isotopes (
149,152,155,161 Tb) have been identified as having suitable physical properties (i.e. half-life (T 1/2 ); emission type and quantity of emitted radiation) for use in cancer treatment and diagnosis. (Table 1) 1-3 . Initial pre-clinical trials 1 have highlighted all four isotopes as being theranostic candidates using a folate-receptor derivative, cm09. Terbium isotopes form stable complexes with DOTA-containing targeting agents which show favourable in-vivo stability, emphasising their suitability for clinical use 1, 4, 5 . Terbium-155 (T 1/2 = 5.32 d 3 ) offers promise as an imaging tracer in single photon emission computed tomography (SPECT), with initial pre-clinical studies indicating excellent image quality even at low doses 4 . The administration of 155 Tb alongside a therapeutic terbium isotope would give a theranostic pair with identical chemical properties; this is particularly advantageous as it facilitates the application of personalised medicine.
Terbium-161 can be generated via neutron activation of a 160 Gd target and subsequent decay of the 161 Gd product to give the desired 161 Tb ( 160 Gd(n,γ) 161 Gd (β − ) 161 Tb) 5 . The other isotopes ( 149,152,155 Tb) have been produced mainly via a proton-induced spallation reaction on a tantalum target combined with on-line mass separation at the CERN-ISOLDE facility [6] [7] [8] . A high percentage of the 1.4 GeV protons delivered by the proton synchrotron booster do not interact with the ISOLDE targets and therefore, the CERN-MEDICIS facility was established to produce isotopes for medical applications by inducing spallation reactions in a secondary target. At CERN-MEDICIS, off-line mass separation is applied to isolate isotopes of the same A/q value 6, 7 . Terbium-155 sources used in this study were collected after mass-separation by implantation of the ion beam (155 A/q) into zinc-coated gold foils. Further chemical separation is still required as mass separation is unable to differentiate between isobaric and pseudo-isobaric species. Removal of the foil matrix is also required.
Alternative methods of producing these isotopes have been investigated (Table 2) 8-15
. However, full-scale production at a radionuclide purity sufficient for clinical studies has not yet been demonstrated.
All lanthanides, especially neighbouring elements, have similar chemical properties due to small differences in their ionic size/charge ratio, making the isolation of high purity individual lanthanide solutions challenging 16 .
www.nature.com/scientificreports www.nature.com/scientificreports/ They exist predominately in the III+ oxidation state under aqueous conditions. The exceptions are europium, which can be selectively reduced to Eu(II) under strongly reducing conditions, and cerium, which can be easily oxidised to Ce(IV). Changes in oxidation state markedly influence chromatographic behaviour and this can be exploited when developing separation methods.
A well-known method of separating lanthanide elements utilises cation-exchange chromatography with α-hydroxyisobutyric acid (α-HIBA) eluent and provides good separation even from neighbouring elements 1, 5, 8 . However, the process is slow and requires precise control of chemical conditions (pH and α-HIBA concentration) to give optimal yield and purity. Attempts to accelerate separation tend to compromise terbium recovery.
A O, which cannot be removed by mass separation. Given its half-life, it constitutes an increasing proportion of overall source activity during transport and storage. In this study, we present a simple method for producing radiologically pure terbium preparations in a chemical form suitable for chelation to targeting molecules as well as for absolute activity measurements and phantom imaging studies. Our aim was to develop a robust, efficient and rapid method capable of isolating terbium from the foil matrix as well as from 139 Ce by selective oxidation. Therefore, ion-exchange and extraction chromatography resins were chosen based on their selectivity for tetravalent over trivalent species.
Results
Chemical separation. Batch separation. In the presence of an oxidant (sodium bromate, NaBrO 3 ) and in HNO 3 solutions commercial UTEVA, TEVA and TK100 extraction resins (Triskem International) and AG1 anion exchange resin (BioRad) all showed pronounced cerium adsorption selectivity over terbium (Fig. 1) . The results imply oxidation of cerium to Ce(IV) was achieved, with terbium remaining in the trivalent state (Tb(III)).
High Ce adsorption (K d = 100-1,000) was observed at high HNO 3 concentrations (8-10 M) on all four resins, whilst terbium adsorption remained minimal (K d = 0.1-10) across the concentration range (Fig. 2) . The best separation resolutions (Equation (2), SR > 100) were obtained using TEVA and UTEVA resins at high HNO 3 concentrations; further studies were conducted on these resins using pre-packed cartridges.
Kinetic studies. UTEVA extraction chromatography resin was chosen to demonstrate kinetic behaviour with the rate of cerium adsorption studied in 10 M HNO 3 /0.1 M NaBrO 3 solutions; rapid adsorption (<60 s) was observed (Fig. 3a) . The rate of cerium oxidation was also studied in 10 M HNO 3 /0.1 M NaBrO 3 solutions. Solutions were filtered under vacuum after a minimum of 60 s in contact with the resin. Rapid oxidation (<90 s) of cerium was observed (Fig. 3b) .
Neither the rate of adsorption nor the rate of oxidation were limiting factors in the separation, suggesting that rapid column separation is achievable under these conditions. Table 1 . Physical properties of four terbium isotopes and their applications in nuclear medicine 1, 2 . EC -electron capture; PET -positron emission tomography; SPECT -single photon emission computed tomography.
Isotope
Nuclear reactions Production facility Incident particle energy References Table 2 . Established and alternative production methods for the four terbium isotopes.
www.nature.com/scientificreports www.nature.com/scientificreports/ Column studies. Column-based separation using a commercially available pre-packed UTEVA cartridge (2 mL) provided effective isolation of terbium from cerium impurities. The elution profile (Fig. 4) shows that terbium (>99%) was removed in the load solution (10 mL, 8 M HNO 3 ) and the subsequent wash solution (10 mL, 8 M HNO 3 ) with minimal cerium impurities remaining (<0.002%). Cerium was successfully recovered by elution from the cartridge in hydrochloric solution (<10 mL, 0.1 M). The column-based separation was repeated using a pre-packed TEVA cartridge (2 mL); however, the separation achieved was less successful as ~0.1% Ce was detected in the Tb fraction under similar conditions (Fig. 4) .
These column studies allowed the development of a separation scheme for the removal of 155 Tb from both 139 Ce isotopic impurities and the zinc-plated gold catcher foil matrix (Fig. 5) . Table 3 ). The scheme detailed in Fig. 5 
Discussion
In many cases, it is essential that suitable radiochemical methods are available to provide radionuclides in sufficient quantities with relatively high specific activity, radionuclidic and chemical purity to facilitate accurate pre-clinical and clinical study. The method described is able to produce high radiological purity 155 Tb sources, suitable for absolute activity, nuclear data and ionisation chamber measurements. The sources are also suitable for bioconjugation, molecular chelation and SPECT imaging studies. Although the 139 Ce impurity discussed here does not possess significant biological toxicity 18 , it is radioactive and, if not removed, would result in an unnecessary additional dose to the patient.
Currently, proton-induced spallation is the main route for producing 155 Tb at CERN for (pre)-clinical studies. The chemical purification method proposed here (Fig. 5) 21 and DOTA-containing targeting molecules 4 and could compete with the target terbium isotope(s), reducing their efficacy. Tb source was provided by CERN-ISOLDE and CERN-MEDICIS in the form of a zinc-coated gold foil. HCl (Trace Analysis Grade, Fisher Scientific) and HNO 3 were used for foil dissolution and NaBrO 3 (Alfa Aesar) for cerium oxidation. 140 Ce and 159 Tb was carried out using a tandem ICP-MS/MS (Agilent 8800) equipped with a collision-reaction cell positioned between two quadrupole mass filters. The instument was run in Single Quad mode, with only the second mass filter operating. The instrument is fitted with a quartz double-pass spray chamber and a MicroMist nebuliser (Glass Expansion, Melbourne, Australia) and nickel sample and skimmer cones (Crawford Scientific, South Lanarkshire, UK). It was tuned daily using a mixed 1 ppb standard solution (Ce, Co, Li, Mg, Tl and Y in 2% v/v HNO 3 ). No Tb activity ratio. The detection system set-up and full-energy peak efficiency calibration is described in detail by Collins et al. 22 . The nuclear data (half-lives and γ-ray emission intensities) used to determine the activities of 155 Tb and 139 Ce were taken from the evaluated database of ENSDF and the DDEP, respectively 3, 17 . As A high purity Ta metal target (Ta647M) made of 12 rolls of Ta foil (99.95% purity, 12 μm thick, 15 mm wide, 2 cm diameter) with a total mass of 357 g was arranged in a 20 cm long Ta tube coupled to a rhenium surface ion source. The target was irradiated with 1.4 GeV protons delivered by the Proton Synchrotron Booster accelerator (CERN, Geneva). The CERN-MEDICIS irradiation target is located in the High Resolution Separator (HRS) beam dump position at ISOLDE (Fig. 6) , and receives a fraction of the scattered 1.8 × 10
Inductively coupled plasma mass spectrometry (ICP-MS). Measurement of stable
18 protons downstream from a primary HRS target (623SiC, ISOLDE physics program). The irradiation was scheduled within the MED004 approved experiment and took place from 27 th September to 1 st October 2018. The irradiated target was then moved to the CERN-MEDICIS isotope mass separator in order to release and extract ion species selected at mass-to-charge ratio of 155 6 . The separated ions were collected on a zinc-plated gold foil and removed on 3 rd October. The following isotopes were implanted upon sample retrieval: 
In all cases, the samples were shaken and left to equilibrate for 24 h. After equilibration, the solutions were filtered to isolate the aqueous phase (Whatman 41 ashless filter paper, 20-25 μm pore size). An aliquot was taken from each sample, diluted with 2% HNO 3 (2% v/v) and analysed by ICP-MS.
The adsorption of Tb and Ce onto each resin was quantified by calculating the distribution coefficient (K d ) using Eq. (1) 24 .
Where (CPS) 0 and (CPS) t are the concentrations of analyte in the aqueous phase before and after equilibration, respectively, V is the volume of solution (mL) and m is the mass of resin used (g). The separation achievable in the different HNO 3 solutions was quantified by calculating the separation factor using Eq. (2).
Kinetic studies. In order to determine the rate at which Ce(IV) and Tb(III) are adsorbed onto UTEVA, a HNO 3 (10 M) solution containing 100 ppb Ce, 100 ppb Tb and sodium bromate (0.1 M) was left for 24 h to allow for the oxidation of Ce(III) to Ce(IV). Aliquots (2 mL) were added to vials containing UTEVA resin (0.1 g) and were left in static conditions before being filtered to isolate the aqueous phase at regular time intervals under vacuum (60 seconds-180 minutes). Likewise, to determine the rate at which Ce is oxidised, an excess of sodium bromate (0.1 M, 0.03 g) was added to a HNO 3 solution (2 mL, 10 M) containing 100 ppb Ce, 100 ppb Tb and 0.1 g of UTEVA resin. Repeat samples were left in static conditions before being filtered to isolate the aqueous phase at regular time intervals under vacuum (90 seconds -180 minutes).
An aliquot of each filtrate was diluted with HNO 3 (2% v/v) before analysis by ICP-MS. Distribution coefficients were calculated using Eq. (1).
Column studies. Column-based separation was studied using a pre-packed 2 mL UTEVA cartridge (50-100 µm, Triskem International). The resin was pre-conditioned with 8 M HNO 3 (20 mL). A HNO 3 solution (10 mL, 8 M) containing 0.1 M NaBrO 3 , 100 ppb Tb and 100 ppb Ce was loaded onto the resin. A wash solution of 10 mL 8 M HNO 3 was added to ensure removal of all Tb from the cartridge. Subsequent elution of Ce was achieved using 20 mL 0.1 M HCl. This separation method was also repeated using a pre-packed 2 mL TEVA cartridge (50-100 µm, Triskem International).
Throughout the separations, 1 mL fractions were collected, diluted with HNO 3 (2% v/v) and analysed by ICP-MS in order to compile an elution profile. Column separations were carried out under gravity (approximate flow rate = 0.3 mL/min).
Method validation with active sample. Three zinc-coated gold foils containing 155 Tb and 139 Ce were received at NPL from CERN-ISOLDE and CERN-MEDICIS. The radionuclides were leached by dissolving the zinc layer in 20 mL 6 M HCl and the gold foil in 20 mL aqua regia. Both layers were dissolved in order to maximise the yield of terbium from the sources received. The combined solution was evaporated gently on a hot plate (~150 °C) to incipient dryness and re-dissolved in a 10 mL 8 M HNO 3 /0.1 M NaBrO 3 solution. An ampoule was prepared for HPGe gamma spectrometry in order to quantify the activity of 155 Tb and 139 Ce present. After analysis, the portion was recombined with the bulk solution.
A pre-packed 2 mL UTEVA cartridge (Triskem International, 50-100 µm) was conditioned with 20 mL 8 M HNO 3 . The 10 mL sample was then loaded onto the column and the fraction collected under gravity. The column was washed with 10 mL 8 M HNO 3 . This fraction was collected, under gravity, and combined with the load fraction. The combined fractions were evaporated gently on a hot plate (~150 °C) to incipient dryness and re-dissolved in 20 mL 0.1 M HCl.
An ampoule of the combined terbium fractions was prepared and analysed by HPGe gamma spectrometry in order to assess the resultant purity of the 155 Tb source after separation. The terbium recovery was calculated as follows: 
(1 )
where R 0,1 and R 0,2 are the count rates of the 105 keV gamma-ray emission before and after separation of the 139 Ce, respectively at the reference time 2017-09-29 12:00 UTC. www.nature.com/scientificreports www.nature.com/scientificreports/
Conclusion
A novel method has been developed for the isolation of 155 Tb from sources produced at CERN-ISOLDE and CERN-MEDICIS, currently the main producers of the isotope. A high purity 155 Tb preparation was successfully recovered from a zinc-coated gold matrix and from 139 Ce impurities using a chromatography-based system. The method was shown to be capable of separating 100 ppb Tb and Ce in a 10 mL solution, equivalent to ~6 GBq 155 Tb and ~0. 25 GBq 139 Ce. The radiologically pure 155 Tb preparation was subsequently used for absolute activity measurements and ion chamber measurements. The preparations are also suitable for phantom imaging and pre-clinical studies.
Data Availability
The data generated and analysed during this study are available, upon reasonable request, from the corresponding author.
